biOasis Technologies Ord Shs BIOAF

Example Janssen licensing deals

[prophetoffactz]

Remix Therapeutics—and its RNA reprogramming technology designed to produce small-molecule therapies—has caught the attention of J&J's Janssen Pharmaceuticals, with the two agreeing to a licensing deal that could exceed $1 billion.

 

 

It’s a deal short on details but high on potential, with only $45 million being provided upfront for research funding. The more than $950 million that remains is contingent on Remix’s therapies reaching a variety of clinical and commercial milestones.
Remix Therapeutics signs Janssen licensing deal that could top $1B | Fierce Biotech
 

Janssen to pay Xencor $50M up front in license deal on prostate-cancer therapies

•  
• •  

• AuthorEphraim Bie
• ThemeHealthcare & Pharmaceuticals

 

Xencor Inc. and Janssen Biotech Inc. entered into a research collaboration and license deal to develop certain antibody therapies for treating patients with prostate cancer.

Specifically, the agreement is focused on the discovery of XmAb bispecific antibodies against a type of protein called CD28. The antibodies can co-stimulate T cells and enhance anti-tumor activity.

Xencor will receive an up-front payment of $50 million and will also be eligible to receive milestone payments and high-single digit to low-double digit percent royalties on net sales.

Janssen to pay Xencor $50M up front in license deal on prostate-cancer therapies | S&P Global Market Intelligence (spglobal.com)

Upon closing of the transaction, Pipeline will receive $50M in an upfront payment from Janssen and separately up to $25M in an equity investment from Johnson & Johnson Innovation – JJDC, Inc. and up to $25M in equity investments from Pipeline’s existing investors. Pipeline is also eligible to receive approximately $1 billion in success-based payments including clinical, regulatory and commercial milestones, as well as tiered double-digit royalty payments, which increase if the co-development option for PIPE-307 is exercised by Pipeline.
Pipeline Therapeutics Announces Global License and Development Agreement for Investigational Neuroscience Therapy, PIPE-307 - Pipeline Therapeutics

Yuhan licences lung cancer asset to Janssen in $1.25bn deal

South Korean pharmaceutical company Yuhan has signed a licensing and cooperation agreement valued at up to $1.25bn with Janssen Biotech to out-license a lung cancer drug candidate called Lazertinib.
Yuhan licences lung cancer asset to Janssen in $1.25bn deal (pharmaceutical-technology.com)
 

Janssen and MeiraGTx Sign $440 Million Deal to Develop Gene Therapies for Eye DiseasesJanssen and MeiraGTx Sign $440 Million Deal to Develop Gene Therapies for Eye Diseases | BioSpace